Aligos Therapeutics (NASDAQ: ALGS) has announced the appointment of Ramón Polo, PharmD, PhD, MBA as senior vice president, head of global regulatory affairs, effective immediately.
Dr. Polo’s extensive background includes leading and overseeing development teams, pharmacovigilance programs, and regulatory strategies. Previous to Aligos, Dr. Polo served as senior vice president, head of global regulatory affairs at Shionogi where he focused on regulatory strategies for therapeutic areas including infectious diseases.
“I am thrilled to welcome Ramón to the leadership team at Aligos,” commented Shushmita Chanda, PhD, DABT, EVP, CDO at Aligos. “As we progress ALG-000184 through the phase 2 B-SUPREME study, Ramón’s extensive regulatory expertise will be a critical component as we think about the future of the program. His experience driving regulatory strategies will help guide Aligos at this pivotal time.”
